IL17A and inflammatory bowel disease: In vitro, 1,25-(OH)2D3 resulted in a reduction of IL-1, IL-6, and IL-17, together with a reduction in TNF-α, as demonstrated in RA, and an increase in IL-4, IL-5, and IL-10 and a reduction in IFN-γ, as demonstrated in IBD [162,163,164,165,166].